Higher LDL-C Levels Research Articles

Evaluation of Anti-Hyperlipidemic Activity of Extracted Alpha-linlenic Acid from Natural Linum Usitatissimum Compared with Atorvastatin in High Fat Diet Induced Rats

Linum Usitatissimum (LU) has a lipid-lowering action in both normal and diabetic animals. Because OS leaves are rich in oil, the present study was conducted to explain the anti-hyperlipidemic and organ-protective effect of LU fixed oil in rats fed with a high fat (HF) diet. LU fixed oil was extracted by hexane and the fatty acids composition identified by GC-MS. Four groups of male Wister rats included a normal control group, a high fat fed-diet (HF) group, a HF group treated with LU fixed oil, and a HF group treated with a reference drug Atorvastatin. The results show that LU fixed oil contains five kinds of fatty acids, of which alpha-linolenic acid was the major fatty acid. LU fixed oil depressed high serum levels of total cholesterol, triglyceride, LDL-C, and AI, whereas no significant effect on HDL-C was observed. LU fixed oil also suppressed high levels of liver cholesterol and triglyceride with no significant effect on both lipids in feces. In addition, LU fixed oil normalized the high serum levels of LDH and CK-MB but no significant effect on high serum levels of ALT, AST, and ALP was obtained. We conclude that treatment with LU fixed oil during the last three weeks of HF diet feeding decreased the high serum lipid profile and expressed anti artherogenic and cardio protective actions against hyperlipidemia. The anti-hyperlipidemic action of OS fixed oil was mainly resulted from the suppression of liver lipid synthesis. Linolenic acid and linoleic acid contained in LU fixed oil were possibly responsible for both lipid-lowering and cardiac protective action against hyperlipidemia.

Cardiometabolic risk factors correlated with the incidence of dysglycaemia in a Brazilian normoglycaemic sample: the Baependi Heart Study cohort

BackgroundDysglycaemia is defined by elevated glucose levels in the blood, commonly characterized by impaired fasting glucose, impaired glucose tolerance, elevated glycated haemoglobin, or diabetes mellitus (DM) diagnosis. The abnormal levels of glucose may occur many years before DM, a condition known as prediabetes, which is correlated with comorbidities such as cardiovascular diseases. Therefore, the aim of this study was to investigate the incidence of prediabetic dysglycaemia and its relationship with cardiometabolic risk factors at a 5-year follow-up, based on an initially normoglycaemic sample in the Baependi Heart Study cohort.MethodsThe data used comes from the Baependi Heart Study cohort, which consists of two periods: cycle 1 (2005–2006) and cycle 2 (2010–2013). For this study, we excluded those who had fasting blood glucose ≥ 100 mg/dL or were taking anti-diabetic medications at baseline, and those that had diabetes diagnosed in cycle 2. Mixed-effects logistic regression models were used to assess the association between cardiometabolic risk factors and the incidence of dysglycaemia, including a familiar random effect such as a cluster.ResultsThe incidence of prediabetic dysglycaemia was 12.8%, and it did not differ between men and women (14.4% and 11.6%, respectively). Two models were analysed to investigate the relationship between cardiometabolic risk factors and the occurrence of prediabetic dysglycaemia. The model that better explained the occurrence of dysglycaemia over the 5 years, after correction, included the waist circumference (WC) (measures and Δ), systolic blood pressure (SBP), HDL-c levels, and age. Although sex was not associated with the incidence of dysglycaemia, women and men showed differences in cardiometabolic risk factors related to glucose impairment: men who developed dysglycaemia showed, in parallel, higher LDL-c levels, TC/HDL-c ratio and DBP measurements; while these parameters remained similar between women who developed dysglycaemia and dysglycaemia-free women, after 5 years.ConclusionsIn an initially normoglycaemic sample of a highly mixed population living in a traditional Brazilian lifestyle, important cardiometabolic risk factors were associated with the occurrence of prediabetic dysglycaemia, and this relationship appeared to be more important in men. These results provide important insights about cardiovascular risk in prediabetic individuals.

Elevated serum lipid level can serve as early signal for metastasis for Non-Small Cell Lung Cancer patients: A retrospective nested case-control study.

Objective: To investigate the association between serum lipid levels in patients with primary non-small cell lung cancer and the risk of developing metastases, a retrospective cohort-based nested case-control study was conducted.Material and method: Patients with primary non-small cell lung cancer admitted to the First and the Third Hospitals of Jilin University from January 2008 through December 2015 were recruited retrospectively based on their electronic medical records. A total of 524 patients were initially considered, consisting of 138 in the case group and 386 as control. Out of these, 110 were finally included in the case group and 110 as control based on additional selection criteria. The following information is collected from all the patients, total cholesterol (TC), low-density lipoprotein (LDL-C), high density lipoprotein (HDL-C) and triglyceride (TG). Logistic regressions were conducted to estimate the odds ratios (ORs) and 95% confidence intervals (95% CI) for non-small cell lung cancer (NSCLC) patients to have metastasis risk when having elevated serum lipid levels. Restricted cubic spline (RCS) curves were used to demonstrate the association between serum lipid levels and the risk of metastasis.Results: Patients with high TC level (P = 0.025, 0R = 1.35, 95% CI: 1.03-1.74) and patients with high LDL-C level (Q4: > 3.47 vs Q1: ≤2.54, P = 0.002, OR = 3.92, 95% CI: 1.31-11.77) are found to have an increased metastasis risk; and their dose-response relationship was validated by our restricted cubic spline analysis (TC: P overall association=0.02, P non-linear association = 0.73; LDL-C: P overall association=0.02, P non-linear association = 0.10). These associations were statistically significant, particularly in men who smoked, never drank, and were 65 years of age or younger. In addition, patients with simultaneously high levels of TC and LDL-C have a 60% increased risk of metastasis compared with patients with high levels of TC and normal LDL-C.Conclusion: Dyslipidemia may be a risk factor for metastasis among NSCLC patients. Examination of serum lipid level on a regular basis can provide early signal of metastasis for NSCLC patients.

Risk factors, comorbiditiEs and Atherogenic dysLipidaemia in Indian YOUNG patients with dyslipidaemia attending hospital/clinic: REAL YOUNG (dyslipidaemia) study.

Objective:To evaluate the pattern of dyslipidaemia, risk factors, and comorbidities in young Indian adults with dyslipidaemia.Methods:A retrospective, multi-centric real-world study included individuals with dyslipidaemia, aged 18 - 45 years, attending to 623 hospitals/clinics across India. Data were collected retrospectively from medical records to note demographics, risk factors (smoking, alcohol consumption, sedentary lifestyle, family history of dyslipidaemia, diabetes mellitus, and hypertension), and clinical details (height, weight, waist circumference, body mass index (BMI), blood pressure, blood sugar, glycated hemoglobin (HbA1c), triglycerides (TG), total cholesterol (TC), low-density lipoproteins (LDL-C), and high-density lipoprotein (HDL-C)).A descriptive analysis and comparative analysis (Mann-Whitney U test and Chi-square test) were done.Results:Of the total 8135 patients, the majority were men (65.0%). Overall, 87.1% of population had one or multiple comorbidities which included the presence of dyslipidaemia alone (12.9%), dyslipidaemia with diabetes and hypertension (39.1%), dyslipidaemia with diabetes (33.6%), and dyslipidaemia with hypertension (14.4%). Sedentary lifestyle was prevalent observation in >50% of the population. Youngest age (18 - 25) group had higher prevalence of hypertriglyceridemia (63.2%), high LDL-C levels (56.8%), and low HDL-C levels (64.6%), while patients from the age group >25 to ≤35 years had the highest incidence of hypercholesterolemia (66.6%). Atherogenic dyslipidaemia was observed in 41.9%, 25.5%, and 23.2% of patients from age groups of ≥18 to ≤25, >25 to ≤35, and >35 to ≤45 years, respectively. Patients with HbA1c ≥6.5% had significantly higher levels of TG, TC, LDL-C, and lower HDL-C compared to those with HbA1c <6.5%.Conclusion:Hypertriglyceridemia, high LDL-C, low HDL-C, and atherogenic dyslipidaemia were prevalent in the young Indian cohort and sedentary lifestyle, and HbA1c ≥ 6.5% were the predominant risk factors of dyslipidaemia.

3259Next-generation sequencing to confirm clinical FH in The Netherlands

Abstract Background Pathogenic variants in the genes encoding the low-density lipoprotein receptor (LDLR), apolipoprotein B100 (APOB) and proprotein convertase subtilisin/kexin type 9 (PCSK9)) are known to cause familial hypercholesterolemia (FH), a disease characterized by high LDL-C levels. We set out to investigate which proportion of patients with extremely elevated LDL-C levels, who were referred for molecular analysis, carry a mutation in any of the three FH genes or other, putative FH genes. Methods Targeted next-generation sequencing of 28 genes involved in lipid metabolism was performed in 1475 clinical FH patients with LDL-C levels &gt;5mmol/L (corresponding with possible, probable and definite FH score according to the Dutch Lipid Clinic Network criteria) and triglyceride levels &lt;4.5 mmol/L. Genetic variants and copy number variants were curated consecutively using specialist analysis software. (Likely) pathogenic variants in LDLR, APOB, or PCSK9 were annotated as FH-causing variants. Results 14.3% of the 1475 patients with clinical FH were heterozygous carriers of a mutation in LDLR, APOB, or PCSK9. This number ranged from 8% in the lowest LDL-C group (5–5.99 mmol/L) to 56% in patients with the highest LDL-C levels (&gt;8 mmol/L). Patients with LDLR, APOB, or PCSK9 variants had median LDL-C levels of 6.8 [5.7–7.9], 6.2 [5.1–7.0], and 6.4 [5.7–6.8] mmol/L [interquartile range], respectively. Mutation-negative FH patients had median LDL-C levels of 5.8 [5.2–6.5] mmol/L. Of the FH mutation-negative patients 7.4% had a (likely) pathogenic variant in the gene encoding lipoprotein lipase (LPL) and 1.3% in the apolipoprotein E (APOE) gene. The proportion of FH mutation-negative patients carrying an APOE variant increased from 1.2% in the lowest LDL-C group to 7.5% in patients with LDL-C &gt;8 mmol/L. Mutation-positive FH patients were significantly younger (41.61±17.53 years vs 52.62±13.28 years P&lt;0.001) and had a significant lower BMI (25.86±4.87 vs 26.55±4.07kg/m2, P=0.02) compared to mutation negative patients. Figure 1 Conclusions A genetic defect in LDLR, APOB or PCSK9 is identified in only 14.3% of the patients with a clinical FH phenotype (defined as LDL-C &gt;5 mmol/L) referred for molecular testing in the Netherlands. Mutations in LPL and APOE were found in a minor proportion of the FH mutation-negative patients. Our finding that a mutation is only found 56% of patients who present with LDL-C levels above 8 mmol/L indicates that either misclassification of FH and/or other genetic defects may be present in this group. Acknowledgement/Funding Grant [016.156.445] from The Netherlands Organisation for Scientific Research (NWO)

P938Extensive formation of atherosclerotic cardiovascular disease in subjects with severe familial hypercholesterolemia defined by the international atherosclerosis society criteria

Abstract Introduction The International Atherosclerosis Society (IAS) has proposed “severe familial hypercholesterolemia (FH)” as a FH phenotype with the highest cardiovascular risk. Coronary artery disease (CAD) represents a major atherosclerotic change in FH patients. Given their higher LDL-C level and atherogenic clinical features, more extensive formation of atherosclerosis cardiovascular disease including not only CAD but stroke/peripheral artery disease (PAD) may more frequently occur in severe FH. Methods 481 clinically-diagnosed heterozygous FH subjects were analyzed. Severe FH was defined as untreated LDL-C&gt;10.3 mmol/l, LDL-C&gt;8.0 mmol/l+ 1 high-risk feature, LDL-C&gt;4.9 mmol/l + 2 high-risk features or presence of clinical ASCVD according to IAS proposed statement. Cardiac (cardiac death and ACS) and non-cardiac (stroke and peripheral artery disease) events were compared in severe and non-severe FH subjects. Results Severe FH was identified in 50.1% of study subjects. They exhibit increased levels of LDL-C and Lipoprotein (a) with a higher frequency of LDLR mutation. Furthermore, a proportion of %LDL-C reduction&gt;50% was greater in severe FH under more lipid-lowering therapy (Table). However, during the observational period (median=6.3 years), severe FH was associated with a 5.9-fold (95% CI, 2.05–25.2; p=0.004) and 5.8-fold (95% CI, 2.02–24.7; p=0.004) greater likelihood of experiencing cardiac-death/ACS and stroke/PAD, respectively (picture). Multivariate analysis demonstrated severe FH as an independent predictor of both cardiac-death/ACS (hazard ratio=3.39, 95% CI=1.12–14.7, p=0.02) and stroke/PAD (hazard ratio=3.38, 95% CI=1.16–14.3, p=0.02) events. Clinical characteristics of severe FH Non-severe FH Severe FH P-value Baseline LDL-C (mmol/l) 5.3±1.5 6.6±2.0 &lt;0.0001 Lp(a) (mg/dl) 15 [8–28] 21 [10–49] &lt;0.0001 LDLR mutation (%) 49.6% 58.9% 0.00398 On-treatment LDL-C (mmol) 133 [106–165] 135 [103–169] 0.9856 %LDL-C reduction&gt;50% 21.3% 49.8% &lt;0.0001 High-intensity statin (%) 13.3% 42.3% &lt;0.0001 PCSK9 inhibitor (%) 6.3% 21.2% &lt;0.0001 Clinical outcome Conclusions Severe FH subjects exhibit substantial atherosclerotic risks for coronary, carotid and peripheral arteries despite lipid lowering therapy. Our finding underscore the screening of systemic arteries and the adoption of further stringent lipid management in severe FH patients.

Risk factors for the development of hyperuricemia: A STROBE-compliant cross-sectional and longitudinal study.

Hyperuricemia has received increasing attention as a major public health problem. This study aims to investigate the risk factors for hyperuricemia and to explore the relationship between changes in biochemical variables and incident hyperuricemia.A cross-sectional and subsequently prospective study was performed among adults who took their health checkups at Zhejiang University Hospital. The participants who were free of hyperuricemia at baseline received annual follow-up examinations during a 6-year period. Cox proportional hazards regression analyses were conducted to calculate the risks for incident hyperuricemia.Of the 9238 participants enrolled, 1704 (18.4%) were diagnosed as hyperuricemia. During 21,757 person-years of follow-up, 1492 incident hyperuricemia cases were identified. The incidence of hyperuricemia was 68.58 cases per 1000 person-year of follow-up in the overall participants. The prevalence and the incidence of hyperuricemia increased greatly in female older than 50 years. High levels of BMI, SBP, FPG, TG, LDL-C, ALT, BUN, and creatinine increased the risk of hyperuricemia. Suffering fatty liver also increased the risk of hyperuricemia. Subjects with increasing DBP, TG, BUN, creatinine, or decreasing HDL-C were more likely to incident hyperuricemia.This study revealed that the change of diastolic blood pressure (DBP), serum triglycerides (TG), blood urea nitrogen (BUN), creatinine, and high-density lipoprotein cholesterol (HDL-C) level were independently associated with incident hyperuricemia.

P5332Magic mirror on the wall, can we reach our LDL-C goal? Comparison of calculated LDL-C and direct measured LDL-C levels in atherogenic dyslipidemia condition

Abstract Background LDL-C represents the primary lipoprotein target for reducing cardiovascular risk. LDL-C can either be calculated or measured directly. Friedewald equation has certain limitations especially with high triglyceride and low LDL-C levels. Although a number of automated direct LDL-C assays are commercially available, non of them is considered to be equivalent to the “gold standard” of direct LDL-C, beta quantitation, a complex and expensive process that is unavailable in routine clinical practice. In atherogenic dyslipidemia condition (ADC) (triglycerides≥2.3 mmol/L and HDL-C&lt;1.0 mmol/L) non-HDL-C and remnant cholesterol are proven additional risk factors. Purpose We compared one of the direct homogeneous assays with the widely used Friedewald's and the new Martin/Hopkins methods of estimation of LDL-C to see the differences in average LDL-C, remnant cholesterol and non-HDL-C levels and in availability of less than 1.8 mmol/L of LDL-C in atherogenic dyslipidemia condition. Methods We investigated 14 906 lipid profiles from fasting blood samples of Hungarian individuals with triglycerides &lt;4.5 mmol/L. Total cholesterol (TC), HDL-C, triglycerides (TG) and direct LDL-C (D-LDL-C) were measured directly by the enzimatic assays. We also estimated calculated LDL-C by the Friedewald's formula (F-LDL-C) and by using the new Martin/Hopkins estimation (MH-LDL-C). We have now prepared first a variant of Martin/Hopkins table in mmol/L, in which the modified adjustable factors of 2.2 are included. We determined also non-HDL-C and remnant cholesterol (RC) as a difference of non-HDL-C and F-LDL-C (F-RC), MH-LDL-C (MH-RC), D-LDL-C (D-RC). Results In the investigated population 19.25% was F-LDL-C, 15.48% MH-LDL-C and 7.92% D-LDL-C below 1.8 mmol/L. ADC occurred at 8.12%. For ADC, when F-LDL-C&lt;1.8 mmol/L (A), mean values for F-LDL-C, MH-LDL-C, D-LDL-C and non-HDL-C were 1.23±0.4; 1.65±0.39; 2.06±0.4 and 2.46±0.5 mmol/L respectively. These mean levels were 1.01±0.36; 1.4±0.3; 1.83±0.3 and 2.15±0.34 mmol/L for MH-LDL-C&lt;1.8 mmol/L (B). For D-LDL-C&lt;1.8 mmol/L (C), mean values were 0.79±0.35; 1.13±0.26; 1.54±0.19 and 1.83±0.25 mmol/L respectively. The average RC values (in mmol/L) for A were F-RC: 1.23±0.36; MH-RC: 0.81±0.18; D-RC: 0.4±0.17, for B 1.14±0.33; 0.74±0.14; 0.32±0.13, and for C 1.04±0.27; 0.70±0.1; 0.29±0.12 respectively. Conclusions The Friedewald equation tends to underestimate and the homogeneous enzimatic direct LDL-C assays to overestimate the LDL-C levels compared to the new, accurate, calculated LDL-C values in atherogenic dyslipidemia condition. Based on the data presented in our investigation we should like to propose that more realistic vasculo-protective lipid status can be attained if we calculate LDL-C using the Martin/Hopkins estimation.

Serum Lipids and Cardiovascular Disease Mortality in Iranian Population: Joint Modeling of Longitudinal and Survival Data in Tehran Lipid and Glucose Study (TLGS) Cohort.

Background: Lipid abnormalities are major risk factors of death from cardiovascular disease (CVD). As well as, lipid markers are time-dependent covariates that change with aging. Previous cohort studies have only investigated baseline measurements of lipid markers on CVD mortality. Materials and Methods: The study sample consisted of 4,148 individuals aged over 40 years. Total cholesterol (TC), LDL-cholesterol (LDL-C), and HDL-cholesterol (HDL-C) were measured in five phases. A joint model analysis was used to investigate the association between each longitudinal lipid markers and CVD mortality in men, women and pooled sample. All analysis was performed using the survival and joint modeling packages in R 3.3.3. Results: Totally, 233 CVD deaths occurred during a median follow-up of 12.4 years. For men, CVD mortality increased by 28% (confidence interval [CI]: 14%,44%) for a 10% increased in TC. For women, CVD mortality increased by 43% (CI: 22%, 68%) and 21% (CI:7%, 37%) for 10 % increase in TC and LDL-C and decreased by 18% (CI:7%, 27%) for a 10% increase in HDL-C. Conclusion: Association of lipid markers with CVD mortality is different in men and women, such that high levels of TC and LDL-C and low levels of HDL-C are risk factors of CVD mortality in women, but only TC is a risk factor of CVD mortality in men.

Artmış Kalıntı Kolesterol Kan Düzeyleri İlk Defa Geçirilen Akut Koroner Sendrom ile İlişkilidir

Introduction: This study aimed to investigate the association between remnant cholesterol and acute coronary syndrome (ACS) and its predictive value for acute coronary syndrome occurring for the first time. Patients and Methods: We compared increasing concentrations of non-fasting remnant cholesterol aside from other lipid profile parameters to investigate this association in 226 patients with ACS for the first time and 192 elective coronary angiography patients with normal coronary arteries. Results: Patients with ACS were mostly males and were younger than those in the control group; moreover, they had higher percentage of diabetes mellitus (for all p< 0.001). Glucose and white blood cell levels at admission were also higher in patients with ACS. Remnant cholesterol level (such as LDL-C) was statistically higher in the ACS group compared with those of the control group (p< 0.001). In the univariate and bivariate binary logistic regression analysis, high blood remnant cholesterol, high blood LDL-C, and low blood HDL-C levels had a predictive value for ACSs. Conclusion: This study demonstrated that remnant cholesterol levels (such as high blood LDL-C levels) are associated with increased risk of ACS for the first time. Further studies should be performed focusing on lowering remnant cholesterol levels apart from lowering LDL-C levels in patients with ACS.

High Lipoprotein(A) Cholesterol In Patients With Familial Hypercholesterolemia

Background and Aims: Familial Hypercholesterolemia (FH) patients have an increased cardiovascular risk due to high TC or LDL-C levels. Lp(a) is a lipoprotein rich in cholesterol and is an independent risk factor for CVD due to prothrombotic/anti-fibrinolytic effects or/and by promoting accelerated atherogenesis. We aim to determine if elevated Lp(a) concentrations can contribute to clinical phenotype of FH.

STUDY ON PRE-HYPERTENSION PREVALENCE AND RELATIONSHIP WITH DYSLIPIDEMIA IN ADULTS AT QUANG NAM PROVINCE

Objectives: To investigate the prevalence, risk factors of prehypertension in QuangNam province of Vietnam. Methods: A case-control study of 3,237 adults (aged ≥ 25 years) was conducted in Quang Nam province, Vietnam in 2017, using questionnaire interviews, clinical examinations, and laboratory tests. Blood pressure, anthropometry, plasma glucose and lipids were measured. The variables contributing significantly to pre-hypertension were analyzed by multiple logistic regression analysis. Results: The prevalence of prehypertension was 30.7%, hypertension 31.6% and normal blood pressure was 37.7%. Lipid disorders such as high total cholesterol levels, high triglyceride levels, high LDL-C levels were significantly higher in prehypertensive than optimal blood pressure (BP). Multivariable logistic regression analysis revealed strong positive associations of pre-hypertension with high triglyceride levels (OR = 1.41, CI 95%: 1.13 - 1.75, p = 0.002); high LDL-C levels (OR = 1.42; CI 95%: 1.03 - 1.97; p = 0,034). The area under the ROC curve of triglyceride, cholesterol, LDL-C was 0.578; 0.566; 0.549, respectively. There was a positive correlation of blood cholesterol, blood triglyceride, blood LDL-C with changes in systolic BP, diastolic BP, and average BP. Conclusions: The prevalence of prehypertension in Quang Nam province of Vietnam was 30.7%. High cholesterol, high triglycerides, high LDL-C level were significantly associated with prehypertension. Key words: Lipid – prehypertension

STUDY ON PRE-HYPERTENSION PREVALENCE AND RELATIONSHIP WITH DYSLIPIDEMIA IN ADULTS AT QUANG NAM PROVINCE

Objectives: To investigate the prevalence, risk factors of prehypertension in QuangNam province of Vietnam. Methods: A case-control study of 3.237 adults (aged ≥ 25 years) was conducted in Quang Nam province, Vietnam in 2017, using questionnaire interviews, clinical examinations, and laboratory tests. Blood pressure, anthropometry, plasma glucose and lipids were measured. The variables contributing significantly to pre-hypertension were analyzed by multiple logistic regression analysis. Results: The prevalence of prehypertension, hypertension and normal blood pressure was 30.7%, 31.6% and 37.7%, respectively. Cardiovascular risk factors such as overweight and obesity, family history of hypertension, alcohol abuse, smoking, diabetes, high total cholesterol levels, high triglyceride levels, high LDL-C levels were significantly greater in prehypertensive compared to optimal blood pressure (BP). Multivariable logistic regression analysis revealed strong positive associations of pre-hypertension with alcohol abuse (OR = 1.68; CI 95%: 1.29-2.20; p &lt; 0.001), diabetes (OR = 3.39; CI 95%: 1.32 - 8.65; p=0.011); high triglyceride levels (OR = 1.41, CI 95%: 1.13 - 1.75, p = 0.002); high LDL-C levels (OR = 1.42; CI 95%: 1.03 - 1.97; p=0.034). There was a positive correlation of cardiovascular risk factors such as BMI, abdominal circumference, blood glucose, blood cholesterol, blood triglyceride, blood LDL-C with changes in systolic BP, diastolic BP, and average BP. Conclusions: The prevalence of prehypertension in Quang Nam province of Vietnam was 30.7%. Risk factors such as alcohol abuse, diabetes, high triglycerides, high LDL-C were significantly associated with prehypertension. Key words: cardiovascular risk factors - hypertension – prehypertension

Atherogenic Impact of Homocysteine: Can HMG-CoA Reductase Inhibitors Additionally Influence Hyperhomocysteinaemia?

Abstract The strong association among the risk of coronary artery diseases (CAD), high levels of LDL-C and low levels of HDLC is well established. Hyperhomocysteinaemia (HHcy) is an independent risk factor for cardiovascular disease (CVD) and causes endothelial dysfunction, a hallmark of atherosclerosis. In this study, we ascertained the influence of statins on the atherogenic index, as an indicator and a significant adjunct for predicting atherosclerosis in hyperhomocysteinaemic male Wistar albino rats. For 4 weeks, the animals were fed with one of the following diets (Mucedola SRL., Milan, Italy): standard rodent chow; a diet enriched in methionine with no deficiency in B vitamins or a diet enriched in methio-nine and deficient in B vitamins. The animals were simultaneously exposed to a pharmacology treatment with atorvastatin at dose of 3 mg/kg/day i.p. or simvastatin, at dose of 5 mg/kg/day i.p. We measured weight gain, food intake, and FER and determined the concentrations of biochemical parameters of dyslipidaemia (TC, TGs, LDL-C, VLDL-C, and HDL-C), AI, and CRR. A histopathological examination was conducted on portions of the right and left liver lobes from each animal. A connection between Hhcy and dyslipidaemia was indicated by the findings of biochemical and histological analyses, suggesting that Hhcy was a pro-atherogenic state. An improvement in the lipid profile along with a decrease in the atherogenic index by statins suggests that atorvastatin and simvastatin could be useful antiatherogenic agents, with protective activities during hyperhomocysteinaemia.

HIV and cART-Associated Dyslipidemia Among HIV-Infected Children.

Background: Persistent dyslipidemia in children is associated with risks of cardiovascular accidents and poor combination antiretroviral therapy (cART) outcome. We report on the first evaluation of prevalence and associations with dyslipidemia due to HIV and cART among HIV-infected Ethiopian children. Methods: 105 cART naïve and 215 treatment experienced HIV-infected children were enrolled from nine HIV centers. Demographic and clinical data, lipid profile, cART type, adherence to and duration on cART were recorded. Total, low density (LDLc) and high density (HDLc) cholesterol values >200 mg/dL, >130 mg/dL, <40 mg/dL, respectively; and/or, triglyceride values >150 mg/dL defined cases of dyslipidemia. Prevalence and predictors of dyslipidemia were compared between the two groups. Results: prevalence of dyslipidemia was significantly higher among cART experienced (70.2%) than treatment naïve (58.1%) children (p = 0.03). Prevalence of low HDLc (40.2% versus 23.4%, p = 0.006) and hypertriglyceridemia (47.2% versus 35.8%, p = 0.02) was higher among cART experienced than naïve children. There was no difference in total hypercholesterolemia and high LDLc levels. Nutrition state was associated with dyslipidemia among cART naïve children (p = 0.01). Conclusion: high prevalence of cART-associated dyslipidemia, particularly low HDLc and hypertriglyceridemia was observed among treatment experienced HIV-infected children. The findings underscore the need for regular follow up of children on cART for lipid abnormalities.

Identification of a Helical Segment within the Intrinsically Disordered Region of the PCSK9 Prodomain

Proprotein convertase subtilisin/kexin 9 (PCSK9) is a key regulator of lipid metabolism by degrading liver LDL receptors. Structural studies have provided molecular details of PCSK9 function. However, the N-terminal acidic stretch of the PCSK9 prodomain (Q31–T60) has eluded structural investigation, since it is in a disordered state. The interest in this region is intensified by the presence of human missense mutations associated with low and high LDL-c levels (E32K, D35Y, and R46L, respectively), as well as two posttranslationally modified sites, sulfated Y38 and phosphorylated S47. Herein we show that a segment within this region undergoes disorder-to-order transition. Experiments with acidic stretch-derived peptides demonstrated that the folding is centered at the segment Y38–L45, which adopts an α-helix as determined by NMR analysis of free peptides and by X-ray crystallography of peptides in complex with antibody 6E2 (Ab6E2). In the Fab6E2–peptide complexes, the structured region features a central 2 1/4-turn α-helix and encompasses up to 2/3 of the length of the acidic stretch, including the missense mutations and posttranslationally modified sites. Experiments with helix-breaking proline substitutions in peptides and in PCSK9 protein indicated that Ab6E2 specifically recognizes the helical conformation of the acidic stretch. Therefore, the observed quantitative binding of Ab6E2 to native PCSK9 from various cell lines suggests that the disorder-to-order transition is a true feature of PCSK9 and not limited to peptides. Because the helix provides a constrained spatial orientation of the missense mutations and the posttranslationally modified residues, it is probable that their biological functions take place in the context of an ordered conformational state.

Relationship between Dyslipidemia, Cultural Factors, and Cardiorespiratory Fitness in Schoolchildren.

BackgroundThe presence of dyslipidemia and behavioral aspects are determinants of cardiovascular risk, especially in childhood and adolescence.ObjectiveTo verify possible relationships between dyslipidemia, cultural factors, and cardiorespiratory fitness (CRF) in schoolchildren.MethodsThis cross-sectional study evaluated a sample of 1,254 children and adolescents between the ages of 7 and 17 from the South of Brazil, 686 of whom were female. Dyslipidemia was defined as increased levels of at least one of the following lipid profile parameters: triglycerides (TG), total cholesterol (TC) and fractions of high (HDL-c) and low-density lipoprotein (LDL-c). Cultural aspects were evaluated by a self-reported questionnaire. Data were analyzed by logistic regression, considering the odds ratios (OR) and confidence intervals (CI) at 95%.ResultsThe results revealed a high prevalence of dyslipidemia (41.9%), which was associated with female sex (OR: 1.56; IC: 1.24-1.96) and overweight/obese status (OR: 1.55; IC: 1.20-2.00). When lipid profile parameters were evaluated separately, high levels of LDL-c were observed to be associated with sedentary school transport (OR: 1.59; IC: 1.20-2.09). Schoolchildren who were overweight/obese had higher chances of elevated levels of TC (OR: 1.40; IC: 1.07-1.84) and TG (OR: 3.21; IC: 1.96-5.26). HDL-c was shown to be related to high television time (OR: 1.59; IC: 1.00-2.54).ConclusionAlterations in lipid parameters are associated with cultural factors, especially those related to sedentary lifestyle and low levels of CRF.

Cardiovascular Risk Factors and Risk Measurement in Patients with Psoriatic Arthritis in a University Hospital

Abstract Background: Psoriatic Arthritis is the spondyloarthritis associated with psoriasis, which is often related to high mortality due to cardiovascular causes. Objectives: To quantify cardiovascular risk factors (hypertension, diabetes, dyslipidemia, obesity and smoking) and to measure risk by the Global Cardiovascular Risk Score in patients with psoriatic arthritis. Methods: Patients with psoriatic arthritis according to the Classification Criteria for Psoriatic Arthritis, aged between 30 and 74 years and without any other clinically manifest chronic inflammatory disease, atherosclerotic disease or heart failure were included. After an interview, clinical examination and data extraction from medical records, risk stratification was performed using a calculator available on the online platform of the Framingham Heart Study. We considered p < 0.05 as significant. Chi-square test and Fisher’s exact test were used to compare frequencies, as well as correlation measurements. Results: 45 patients were included, 68,9% of which were women and the mean age was 53,94 years. Dyslipidemia was confirmed in approximately 93%, hypertension in 46%, obesity in 40%, 33.3% were diabetics and, 13.3%, smokers; 95% had increased abdominal circumference. It was observed that 53% had high cardiovascular risk, 29% had intermediate risk and 18% had low risk. Individuals with altered C-reactive protein and erythrocyte sedimentation rate presented, respectively, higher levels of LDL-C and total cholesterol. Conclusions: There was a high occurrence of risk factors and the majority of the sample was stratified into high or intermediate cardiovascular risk.

Characteristics of patients with dyslipidemia treated in routine care setting in China

Objective: To describe characteristics of patients with dyslipidemia treated in routine care in China overall and stratified by diabetes and atherosclerotic cardiovascular disease (ASCVD).Methods: This study used data from a cross-sectional survey conducted in China in 2017 under the Dyslipidemia Disease Specific Programme (DSP). Each surveyed physician provided information including demographics, dyslipidemia diagnosis and treatment history, lab values on at least 8 patients currently treated for dyslipidemia with oversampling of patients with ASCVD or diabetes mellitus diagnosis at the time of survey. A related patient survey assessed treatment adherence and satisfaction.Results: This study included 195 physicians (40 endocrinologists, 75 internists, 80 cardiologists) who provided data on 1870 patients (852 with diabetes; 1018 patients without diabetes). Among patients with diabetes, 279 had ASCVD and 573 did not (non-ASCVD). In the diabetic population, patients with ASCVD were older (67.3 vs. 62.1 years), more often had caregiver support (34 vs. 14%), and had higher average LDL-C at diagnosis (172.4 vs. 167.4 mg/dL) compared to their non-ASCVD counterparts. Findings were similar for non-diabetic patients (ASCVD: 323 patients; non-ASCVD: 695) patients. In all four subgroups, 46–54% of patients reported low treatment adherence, and fewer than half expressed satisfaction with their cholesterol control, and 2–5% had LDL-C < 70 mg/dL at their most recent assessment.Conclusions: Among patients with dyslipidemia, those with ASCVD had higher LDL-C levels than patients without ASCVD, and many required caregiving. Low levels of treatment adherence, LDL-C control, and patient satisfaction suggest opportunities to improve care for Chinese patients with dyslipidemia.

Consumo de alcohol y perfil lipidico en participantes del Estudio Longitudinal de Salud del Adulto (ELSA-Brasil)

Introduction: dyslipidemias are commonly defined by low levels of HDL-c and high levels of triglycerides and LDL-c as an alteration in the functioning of lipoproteins. Several factors are related to this pathogenesis, and one of them is the consumption of alcohol, presenting divergences between the amount and the type of alcoholic drink that must be consumed to find effects of association with the lipid parameters. Objective: to investigate the relationship between alcohol consumption and the type of alcoholic beverage with HDL-c and triglycerides in participants of the Longitudinal Study of Adult Health (ELSA-Brazil). Methods: observational, cross-sectional study, developed from baseline data from the ELSA-Brazil (2008-2010). The consumption of alcoholic beverages was estimated in doses/week and categorized in tertiles (1-7, 7-14 and > 14 doses/week) and by type of alcoholic beverage (beer, wine and distillates). Lipid parameters were used as continuous data. Linear regression models were performed for each type of alcoholic beverage. The confidence level was 5%. Results: HDL-c and triglycerides increased with the increase in the number of doses/week of beer. The consumption of wine between 1-7 and 7-14 doses/week raises HDL-c. Conversely, triglycerides tend to decrease when consumption is 1-7 doses/week. Consumption of distillates > 14 doses/week increase HDL-c. Conclusion: HDL-c increased plasma levels directly with the consumption of all types of alcoholic beverages. Conversely, triglycerides decrease with wine consumption.